KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Inventory (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Change in Inventory data on record, last reported at $20.2 million in Q4 2025.

  • For Q4 2025, Change in Inventory fell 61.18% year-over-year to $20.2 million; the TTM value through Dec 2025 reached $87.0 million, down 33.33%, while the annual FY2025 figure was $87.0 million, 33.33% down from the prior year.
  • Change in Inventory reached $20.2 million in Q4 2025 per AMRX's latest filing, down from $30.8 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $52.0 million in Q4 2024 and bottomed at -$16.6 million in Q4 2021.
  • Average Change in Inventory over 5 years is $24.8 million, with a median of $23.2 million recorded in 2023.
  • The widest YoY moves for Change in Inventory: up 630.13% in 2021, down 150.3% in 2021.
  • A 5-year view of Change in Inventory shows it stood at -$16.6 million in 2021, then soared by 166.57% to $11.1 million in 2022, then skyrocketed by 108.58% to $23.1 million in 2023, then skyrocketed by 125.14% to $52.0 million in 2024, then crashed by 61.18% to $20.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Inventory were $20.2 million in Q4 2025, $30.8 million in Q3 2025, and $22.8 million in Q2 2025.